Page last updated: 2024-08-23

raloxifene hydrochloride and Uterine Neoplasms

raloxifene hydrochloride has been researched along with Uterine Neoplasms in 46 studies

Research

Studies (46)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (15.22)	18.2507
2000's	32 (69.57)	29.6817
2010's	6 (13.04)	24.3611
2020's	1 (2.17)	2.80

Authors

Authors	Studies
Bryant, HU; Cohen, IR; Dally, RD; Dodge, JA; Fong, KC; Frank, SA; Geiser, AG; Hinklin, R; Hummel, CW; Jones, SA; Lewis, G; McCann, DJ; Rudmann, DG; Shepherd, TA; Tian, H; Wallace, OB; Wang, M; Wang, Y	1
Shieh, Y; Tice, JA	1
Brito, LG; Candido Dos Reis, FJ; Ferriani, RA; Martins, WP; Moroni, RM; Nastri, CO; Vieira, CS	1
Neves-E-Castro, M	1
Castle, PE	1
Lethaby, A; Vollenhoven, B	1
Cecchini, RS; Costantino, JP; Cronin, WM; Ford, LG; Runowicz, CD; Vogel, VG; Wickerham, DL; Wolmark, N	1
Creasman, WT	1
Chen, XY; Deng, L; Wu, T; Xie, L; Yang, J	1
Lombardi, G; Morelli, M; Nappi, C; Orio, F; Palomba, S; Panici, PL; Pellicano, M; Russo, T; Zullo, F; Zupi, E	1
Colao, A; Lombardi, G; Mastrantonio, P; Morelli, M; Nappi, C; Orio, F; Palomba, S; Pellicano, M; Russo, T; Zullo, F	1
Colao, A; Lombardi, G; Nappi, C; Orio, F; Palomba, S; Panici, PL; Russo, T; Tauchmanovà, L; Zullo, F; Zupi, E	1
Touraine, P	1
Amant, F; Joubert, A; Lindeque, BG; Lottering, ML; Thaver, V; Vergote, I	1
Smith, RE	1
Crans, G; Eppel, W; Jirecek, S; Lee, A; Pavo, I; Wenzl, R	1
Colao, A; Lombardi, G; Mastrantonio, P; Nappi, C; Orio, F; Palomba, S; Russo, T; Sammartino, A; Sbano, FM; Zullo, F	1
Cascella, T; Doldo, P; Falbo, A; Lombardi, G; Mastrantonio, P; Nappi, C; Orio, F; Palomba, S; Russo, T; Zullo, F	1
Lombardi, G; Orio, F; Palomba, S; Zullo, F	1
Christopoulos, S; Rivera, JA; Small, D; Trifiro, M	1
Amati, A; Falbo, A; Orio, F; Palomba, S; Russo, T; Zullo, F	1
de Los Angeles, MM; Goldberg, GL; Goldman, NA; Jones, JG	1
Cimini, V; Falbo, A; Lombardi, G; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F	1
Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Lippman, SM; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N	1
Vastag, B	1
Baytur, YB; Cilaker, S; Koyuncu, FM; Kurtul, O; Lacin, S; Oruc, S; Ozbilgin, K	1
Benetti-Pinto, CL; De Angelo-Andrade, LA; Petta, CA; Soares, PM	1
Asselin, E; Bélanger, G; Boucher, V; Déry, MC; Leblanc, K; Parent, S; Sexton, E	1
Chen, W; Liu, J; Maruo, T; Matsuo, H; Wang, J; Xu, Q	1
Lingxia, X; Taixiang, W; Xiaoyan, C	1
Labrie, F	1
Lethaby, AE; Vollenhoven, BJ	1
Chen, X; Wu, T; Xie, L	1
Fuchs-Young, R; Hale, L; Howe, S; Miles, R; Walker, C	1
Nelson, NJ	1
Jordan, VC	1
Fuchs-Young, R; Nicosia, SV; O'Brien, WF; Porter, GW; Porter, KB; Spellacy, WN; Tsibris, JC	1
Eppes, PG; Wilson, CT; Wozniak, TF	1
Affinito, P; Di Carlo, C; Nappi, C; Palomba, S; Sammartino, A; Zullo, F	1
Pfeilschifter, J	1
Ang, WC; Farrell, E; Vollenhoven, B	1
Katzenellenbogen, BS; Katzenellenbogen, JA	1
Gottardis, MM; Jordan, VC; Satyaswaroop, PG	1

Reviews

15 review(s) available for raloxifene hydrochloride and Uterine Neoplasms

Article	Year
Medications for Primary Prevention of Breast Cancer. JAMA, 2020, 07-21, Volume: 324, Issue:3 Topics: Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Primary Prevention; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms; Venous Thromboembolism	2020
Add-back therapy with GnRH analogues for uterine fibroids. The Cochrane database of systematic reviews, 2015, Mar-20, Issue:3 Topics: Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Estriol; Female; Gonadotropin-Releasing Hormone; Humans; Isoflavones; Leiomyoma; Medroxyprogesterone; Norpregnenes; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Uterine Hemorrhage; Uterine Neoplasms	2015
Association of ovarian and uterine cancers with postmenopausal hormonal treatments. Clinical obstetrics and gynecology, 2008, Volume: 51, Issue:3 Topics: Estrogen Replacement Therapy; Estrogens; Female; Humans; Norpregnenes; Ovarian Neoplasms; Postmenopause; Progestins; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Uterine Neoplasms	2008
Fibroids (uterine myomatosis, leiomyomas). BMJ clinical evidence, 2011, Jan-11, Volume: 2011 Topics: Humans; Leiomyoma; Menopause; Pain; Premenopause; Progestins; Raloxifene Hydrochloride; Regression Analysis; Uterine Neoplasms	2011
Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. The Cochrane database of systematic reviews, 2012, Oct-17, Volume: 10 Topics: Adult; Female; Humans; Leiomyoma; Leuprolide; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Uterine Neoplasms; Young Adult	2012
[SERMs and uterus]. Annales de medecine interne, 2003, Volume: 154, Issue:2 Topics: Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms; Uterus	2003
A review of selective estrogen receptor modulators and national surgical adjuvant breast and bowel project clinical trials. Seminars in oncology, 2003, Volume: 30, Issue:5 Suppl 16 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Risk; Sarcoma; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms	2003
Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:7 Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brachial Plexus Neuropathies; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasms; Nitriles; Radiography, Thoracic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Triazoles; Uterine Neoplasms	2004
Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. The Cochrane database of systematic reviews, 2007, Apr-18, Issue:2 Topics: Female; Humans; Leiomyoma; Leuprolide; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Uterine Neoplasms	2007
Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nature clinical practice. Endocrinology & metabolism, 2007, Volume: 3, Issue:8 Topics: Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone; Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms	2007
An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Best practice & research. Clinical obstetrics & gynaecology, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Estrogen Antagonists; Evidence-Based Medicine; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Norpregnenes; Premenopause; Progestins; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Uterine Neoplasms	2008
Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. The Cochrane database of systematic reviews, 2007, Oct-17, Issue:4 Topics: Female; Humans; Leiomyoma; Leuprolide; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Uterine Neoplasms	2007
Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. Journal of the National Cancer Institute, 1998, Jul-01, Volume: 90, Issue:13 Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transforming Growth Factor alpha; Uterine Neoplasms	1998
[Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis]. Der Orthopade, 2001, Volume: 30, Issue:7 Topics: Administration, Oral; Age Factors; Aged; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Time Factors; Uterine Neoplasms	2001
Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review. Climacteric : the journal of the International Menopause Society, 2001, Volume: 4, Issue:4 Topics: Animals; Disease Models, Animal; Estrogen Replacement Therapy; Female; Humans; Leiomyoma; Norpregnenes; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms	2001

Trials

12 trial(s) available for raloxifene hydrochloride and Uterine Neoplasms

Article	Year
Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:8 Topics: Adult; Estrogen Antagonists; Female; Humans; Leiomyoma; Pilot Projects; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Single-Blind Method; Treatment Outcome; Uterine Neoplasms	2002
Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:10 Topics: Adult; Body Mass Index; Bone and Bones; Bone Density; Calcium; Delayed-Action Preparations; Female; Femur; Humans; Leiomyoma; Leuprolide; Lumbar Vertebrae; Middle Aged; Osteoporosis; Phosphorus; Placebos; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uterine Neoplasms	2002
Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Human reproduction (Oxford, England), 2002, Volume: 17, Issue:12 Topics: Delayed-Action Preparations; Female; Hot Flashes; Humans; Leiomyoma; Leuprolide; Menorrhagia; Pain; Patient Dropouts; Placebos; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Ultrasonography; Uterine Neoplasms	2002
Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertility and sterility, 2004, Volume: 81, Issue:1 Topics: Adult; Estradiol; Female; Follicle Stimulating Hormone; Humans; Leiomyoma; Middle Aged; Premenopause; Prolactin; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Testosterone; Thyrotropin; Thyroxine; Ultrasonography; Uterine Neoplasms	2004
Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene. Human reproduction (Oxford, England), 2004, Volume: 19, Issue:2 Topics: Adult; Blood Glucose; Body Constitution; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Female; Folic Acid; Homeostasis; Homocysteine; Humans; Insulin; Insulin Resistance; Leiomyoma; Leuprolide; Lipids; Middle Aged; Placebos; Premenopause; Raloxifene Hydrochloride; Triglycerides; Uterine Neoplasms; Vitamin B 12	2004
Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Human reproduction (Oxford, England), 2004, Volume: 19, Issue:6 Topics: Antineoplastic Agents, Hormonal; Blood Glucose; Bone Density; Bone Remodeling; Delayed-Action Preparations; Drug Therapy, Combination; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Leuprolide; Lipids; Longitudinal Studies; Middle Aged; Patient Dropouts; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Severity of Illness Index; Treatment Outcome; Uterine Neoplasms; Vasomotor System	2004
Gonadotropin-releasing hormone agonist with or without raloxifene: effects on cognition, mood, and quality of life. Fertility and sterility, 2004, Volume: 82, Issue:2 Topics: Adult; Affect; Analysis of Variance; Cognition; Estrogen Antagonists; Female; Gonadotropin-Releasing Hormone; Humans; Italy; Leiomyoma; Patient Selection; Placebos; Premenopause; Quality of Life; Raloxifene Hydrochloride; Single-Blind Method; Socioeconomic Factors; Uterine Neoplasms	2004
Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women. Fertility and sterility, 2005, Volume: 84, Issue:1 Topics: Apoptosis; Cell Proliferation; Double-Blind Method; Female; Growth Inhibitors; Humans; Leiomyoma; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Uterine Neoplasms	2005
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006, Jun-21, Volume: 295, Issue:23 Topics: Adult; Aged; Breast Neoplasms; Cataract; Cause of Death; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Myocardial Ischemia; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thrombosis; Uterine Neoplasms	2006
A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. European journal of obstetrics, gynecology, and reproductive biology, 2007, Volume: 135, Issue:1 Topics: Adult; Antineoplastic Agents, Hormonal; Female; Genes, bcl-2; Goserelin; Humans; Leiomyoma; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tumor Suppressor Protein p53; Uterine Neoplasms	2007
Drugs can reduce the incidence of breast cancer: now what? Delaware medical journal, 1999, Volume: 71, Issue:9 Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Premenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms	1999
Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertility and sterility, 2001, Volume: 76, Issue:1 Topics: Double-Blind Method; Estrogen Antagonists; Female; Humans; Leiomyoma; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Treatment Outcome; Ultrasonography; Uterine Neoplasms; Uterus	2001

Other Studies

19 other study(ies) available for raloxifene hydrochloride and Uterine Neoplasms

Article	Year
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats. Journal of medicinal chemistry, 2005, Nov-03, Volume: 48, Issue:22 Topics: Animals; Binding Sites; Biological Availability; Cell Line; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Leiomyoma; Mammary Glands, Animal; Models, Molecular; Naphthalenes; Organ Size; Ovary; Piperidines; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Uterine Neoplasms; Uterus	2005
Do selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trials. International journal of cancer, 2011, Feb-15, Volume: 128, Issue:4 Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Neoplasms	2011
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). American journal of obstetrics and gynecology, 2011, Volume: 205, Issue:6 Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Hyperplasia; Estrogen Antagonists; Female; Follow-Up Studies; Hot Flashes; Humans; Incidence; Leiomyoma; Middle Aged; Ovarian Cysts; Polyps; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Uterine Neoplasms; Vaginal Discharge	2011
What is the significance of gynecologic symptoms in the participants in the NSABP study? American journal of obstetrics and gynecology, 2011, Volume: 205, Issue:6 Topics: Breast Neoplasms; Female; Humans; Leiomyoma; Raloxifene Hydrochloride; Tamoxifen; Uterine Neoplasms	2011
ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999). International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2002, Volume: 79, Issue:3 Topics: Adult; Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular System; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms	2002
2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth. Gynecologic oncology, 2003, Volume: 91, Issue:2 Topics: Antineoplastic Agents, Hormonal; Carcinosarcoma; Cell Cycle; Cell Division; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Progesterone; Raloxifene Hydrochloride; Tamoxifen; Triptorelin Pamoate; Uterine Neoplasms	2003
Does raloxifene inhibit the growth of uterine fibroids? Fertility and sterility, 2004, Volume: 81, Issue:6 Topics: Cell Division; Female; Humans; Leiomyoma; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uterine Neoplasms	2004
Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene. Obstetrics and gynecology, 2005, Volume: 105, Issue:5 Pt 2 Topics: Biopsy, Needle; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Immunohistochemistry; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Osteoporosis, Postmenopausal; Ovariectomy; Radiotherapy, Adjuvant; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Neoplasms	2005
Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs. Journal of the National Cancer Institute, 2006, Jun-07, Volume: 98, Issue:11 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Contraindications; Controlled Clinical Trials as Topic; Drug Approval; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Thromboembolism; Treatment Outcome; United States; United States Food and Drug Administration; Uterine Neoplasms	2006
Pulmonary benign metastasizing leiomyoma: a report of 2 cases with different outcomes. The Journal of reproductive medicine, 2006, Volume: 51, Issue:9 Topics: Adult; Estrogen Antagonists; Female; Humans; Leiomyomatosis; Lung; Lung Neoplasms; Middle Aged; Myometrium; Ovariectomy; Raloxifene Hydrochloride; Treatment Outcome; Uterine Neoplasms	2006
Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens. International journal of oncology, 2007, Volume: 30, Issue:2 Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Prohibitins; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen; Uterine Neoplasms	2007
Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro. Human reproduction (Oxford, England), 2007, Volume: 22, Issue:5 Topics: Adult; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Estradiol; Female; Humans; In Situ Nick-End Labeling; Leiomyoma; Middle Aged; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured; Uterine Neoplasms	2007
Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Molecular carcinogenesis, 1996, Volume: 17, Issue:3 Topics: Animals; Cell Division; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Leiomyoma; Phenotype; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Uterine Neoplasms	1996
Anti-estrogens come of age: a pioneer looks back. Journal of the National Cancer Institute, 1998, May-06, Volume: 90, Issue:9 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Female; Humans; Menopause; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Uterine Neoplasms	1998
Effects of raloxifene in a guinea pig model for leiomyomas. American journal of obstetrics and gynecology, 1998, Volume: 179, Issue:5 Topics: Animals; Estradiol; Estrogen Antagonists; Female; Guinea Pigs; Leiomyoma; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Ultrasonography; Uterine Neoplasms	1998
Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated. Prescrire international, 2000, Volume: 9, Issue:50 Topics: Breast Neoplasms; Clinical Trials as Topic; Contraindications; Diabetes Mellitus; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spinal Fractures; Thromboembolism; Uterine Neoplasms	2000
Raloxifene: new preparation. Not better than oestrogen. Prescrire international, 1999, Volume: 8, Issue:44 Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Neoplasms	1999
Biomedicine. Defining the "S" in SERMs. Science (New York, N.Y.), 2002, Mar-29, Volume: 295, Issue:5564 Topics: Breast; Breast Neoplasms; DNA; Drug Resistance, Neoplasm; Estradiol; Estrogen Replacement Therapy; Female; Histone Acetyltransferases; Humans; Ligands; Macromolecular Substances; Nuclear Receptor Coactivator 1; Organ Specificity; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Response Elements; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors; Uterine Neoplasms; Uterus	2002
Tamoxifen-stimulated growth of human endometrial carcinoma. Annals of the New York Academy of Sciences, 1991, Volume: 622 Topics: Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Clomiphene; Enclomiphene; Endometrium; Estradiol; Estrogen Antagonists; Female; Humans; Mice; Mice, Inbred BALB C; Nafoxidine; Neoplasm Transplantation; Piperidines; Polyunsaturated Alkamides; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Uterine Neoplasms	1991